Freenome says updated SimpleScreen CRC blood test lifts advanced precancerous lesion sensitivity to 18.2% in validation study

• Freenome announced late-breaking validation results for an updated SimpleScreen CRC blood test slated for presentation at ACG 2026.
• The updated version improved detection of advanced precancerous colorectal lesions, supporting a prevention-focused screening positioning.
• Colorectal cancer detection held steady versus the first-generation test, which won FDA clearance in July 2026.
• Abbott Cancer Diagnostics launched the first-generation test commercially in the US in late September.
• The new dataset is scheduled for an Oct. 14 oral presentation in Nashville.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Freenome Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610111300PRIMZONEFULLFEED9843006) on October 11, 2026, and is solely responsible for the information contained therein.